Seattle-based biotech company Athira Pharma is laying off 49 people, or about 70% of its workforce, as part of cost-cutting measures and a restructuring. Athira, which went public in 2020 ...

Athira Pharma, a small drugmaker focused on neuroscience, is looking into the different paths it could take to “maximizing stockholder value,” after the company’s most advanced experimental ...

Athira Pharma’s tumultuous journey to phase 2/3 Alzheimer’s disease data has ended in failure. The trial found fosgonimeton was no better than placebo on the primary and key secondary ...

Athira Pharma has been on a bumpy road in recent years, and, now, the company is restructuring and shedding weight to try to keep the journey going. Just a couple of weeks after announcing that ...

BOTHELL, Wash., July 09, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal ...

Athira Pharma (NASDAQ:ATHA) shares fell over 75% after the company said fosgonimeton, its experimental therapy for Alzheimer's disease, failed in a Phase 2/3 trial, prompting at least two Wall ...

Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 ...

Athira Pharma said that Alzheimer’s patients who received its experimental injection fosgonimeton did not decline at a significantly slower rate than patients who received a placebo injection.

BOTHELL, Wash., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health ...

Looking at Athira Pharma, Inc.'s (NASDAQ:ATHA ) insider transactions over the last year, we can see that insiders were net buyers. That is, there were more number of shares purchased by insiders ...

From what we can see, insiders were net buyers in Athira Pharma, Inc.'s (NASDAQ:ATHA ) during the past 12 months. That is, insiders acquired the stock in greater numbers than they sold it.